COMMUNIQUÉS West-GlobeNewswire

Globus Medical Reports Fourth Quarter and Full Year 2023 Results

20/02/2024 - 22:15

AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, [...]

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

20/02/2024 - 22:05

REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it [...]

Arvinas Announces Chief Financial Officer Transition

20/02/2024 - 22:05

- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a [...]

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

20/02/2024 - 22:05

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM remains listed on Euronext Paris as its primary trading market Nasdaq delisting will [...]

PHAXIAM Therapeutics annonce son intention de procéder au retrait volontaire de ses « American Depositary Shares » du Nasdaq Capital Market

20/02/2024 - 22:05

PHAXIAM reste cotée sur Euronext Paris, son marché principal Le retrait de la cote du Nasdaq réduira considérablement la consommation de trésorerie de PHAXIAM et permettra à la Société de concentrer ses ressources [...]

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20/02/2024 - 22:05

NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

20/02/2024 - 22:05

BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating [...]

Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ Expansion

20/02/2024 - 22:05

Fortrea’s non-commercial specialty pharmacy expansion delivers flexible, scalable solutions to customers and life-changing medications direct to patients DURHAM, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: [...]

NurExone’s Intellectual Property Portfolio Expands

20/02/2024 - 22:05

Innovations and know-how in exosome production suited for many clinical applications TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “ [...]

ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

20/02/2024 - 22:05

PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will report its fourth [...]

Teladoc Health Reports Fourth Quarter and Full Year 2023 Results

20/02/2024 - 22:05

Fourth quarter 2023 revenue increase of 4% and full year 2023 revenue increase of 8% to $2,602.4 million Fourth quarter 2023 net loss of $28.9 million , or $0.17 per share, and full year 2023 net loss of $220.4 million [...]

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

20/02/2024 - 22:01

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today [...]

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET

20/02/2024 - 22:01

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

20/02/2024 - 22:01

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]

Caira Surgical to Showcase Radar Surgical Tracking Technology at LSI USA '24 Emerging Medtech Summit

20/02/2024 - 21:55

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Caira Surgical, the pioneer in Radar Surgical Tracking for robotic and navigated joint replacement surgery, today announced its upcoming participation in the prestigious LSI [...]

CorVel Earns 2024 Great Place To Work Certification™

20/02/2024 - 18:09

FORT WORTH, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ:CRVL), is proud to be Certified™ by Great Place To Work ® for the 4th year in a row. The prestigious award is based entirely on what current [...]

New report exposes harmful impact of Ford government’s privatization scheme on local public hospitals: Health Coalition

20/02/2024 - 18:06

Attn: Assignment Editor TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- As the Ford government counters horror stories about unprecedented emergency department wait times, burgeoning deficits, and an unrelenting staffing [...]

IBA – Transparency Notification

20/02/2024 - 18:00

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 20, 2024 06:00 Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]

IBA - PUBLICATION RELATIVE À UNE NOTIFICATION DE TRANSPARENCE

20/02/2024 - 18:00

(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 20 février 2024, 18 :00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]